Astilbin Inhibits the Proliferation and Induces Apoptosis of Gastric Cancer Cells (AGS) by Targeting the Key Inflammatory Markers

Abstract

Background: The predisposition toward gastrointestinal disease is increasing as a result of dietary changes and overindulgence in food preparation. Ninety percent of stomach cancers are adenocarcinomas, a type of cancer of the gastrointestinal tract that is the leading cause of mortality worldwide.Purpose: Astilbin, a natural dihydroflavonol substance derived from a range of foods and medicinal herbs, has been shown in the current study to have anticancer potential against gastric cancer in AGS cell lines.Materials and Methods: The half maximal inhibitory concentration value was determined after astilbin was given to AGS cell lines at various doses. To verify apoptosis, the astilbin-treated cell line was subsequently stained with the dual dye acridine orange/ethidium bromide. AGS cell lines, the enzyme-linked immunosorbent assay (ELISA) approach was also used to investigate the inflammatory cytokines. Using ELISA, apoptotic marker expression including Bcl-2-associated X-protein, caspase-9 proteins, and B-cell lymphoma 2 was assessed in gastric cancer cells treated with astilbin.Results: The study’s findings reveal that astilbin is a prime candidate for gastric cancer therapy since it causes apoptosis in AGS cells and has a stronger effect on the major inflammatory markers of the disease.Conclusion: The study provides comprehensive methodologies and tools for predicting absorption, distribution, metabolism, excretion, and toxicity properties, facilitating informed decision-making in the development and optimization of astilbin as a gastric cancer therapy.

Keywords: Astilbin; gastric cancer; AGS; apoptosis; proliferation; inflammatory markers